Please check the following:
- {{error.value}}
FREE membership
FREE membership
Join InvestSMART today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Start your free 15 day trial now' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
OR
Sign up with
Login with
By continuing, you agree to our
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
Looks you are already a member. Please enter your password to proceed
OR
Sign up with
Login with
By continuing, you agree to our
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
OR
Sign up with
Login with
By continuing, you agree to our
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Check your inbox
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Noxopharm Limited (ASX:NOX)
ALERT: Price-sensitive ASX Announcement for NOX
Current share price for NOX : $0.094 -0.011 (-10.48%)+
Announcement
Release
8 Sep 2025 9:25AM
Price at Release
$0.105
Full Release
Summary
Noxopharm Limited announced the successful completion of the fourth and final single-dose cohort of the HERACLES clinical trial, which tested SOF-SKN™, a drug candidate for autoimmune diseases, at varying concentrations. Conducted in Australia, the trial leveraged local expertise in lupus research and secured federal R&D tax incentives. SOF-SKN was found to be safe and well-tolerated at the highest dose, marking a significant milestone in its development for treating cutaneous lupus erythematosus (CLE) and potentially other autoimmune diseases. The company plans to provide updates on the next steps for the HERACLES trial, addressing a market valued over US$3.3 billion.
Key Points
- Fourth and last single-dose cohort of SOF-SKN completed safely.
- HERACLES trial conducted in Australia for SOF-SKN.
- SOF-SKN developed for cutaneous lupus erythematosus (CLE).
- Australian expertise and federal R&D tax benefits leveraged.
- SOF-SKN found safe and well tolerated at highest dose.
- Noxopharm plans to update on next steps for HERACLES.
- Potential applications in rheumatoid arthritis and other autoimmune diseases.
- Global cutaneous lupus market over US$3.3 billion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
